Foundation Medicine

Dedicated to advancing personalised healthcare

Molecular information and genomic analysis play an increasingly important role in medicine and diagnostics solutions, especially for cancer patients.

Foundation Medicine is a molecular information company dedicated to increasing personalised healthcare via a deep understanding of the molecular changes that contribute to diseases such as cancer.

Foundation Medicines offers a full suite of comprehensive genomic profiling (CGP) assays to identify the molecular alterations in an individual patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.

In Australia, Roche’s pharmaceutical division is the licensed distributor of FoundationOne®CDx, FoundationOne®Liquid CDx and FoundationOne®Heme, offering CGP services and decision support tools that may inform clinical care in cancer.

Healthcare professionals who would like more information about Roche Foundation Medicine services may go to or contact Roche Medical Information on 1800 233 950 or Orders may be placed by medical doctors through Healthcare professionals who have not previously registered for RocheInteract will be prompted to register before an order can be placed.

Genomic profiling (also known as genetic sequencing) uses laboratory and computational methods to read the blueprint of cancer cells (the tumour DNA sequence). Compared to normal cells, cancer cells have a blueprint that contain errors. These errors lead to abnormal growth of tumour cells. Understanding what errors are present in the tumour cells may be useful in informing treatment options.

Patients wanting more information about cancer tumour testing should speak with their doctor. Only medical doctors are able to order a Foundation Medicine test.

FoundationOneCDx is for solid tumours; FoundationOneHeme is for haematologic cancers or sarcomas. FoundationOneLiquid is a liquid biopsy test for solid tumours. FoundationOne reports may contain information regarding treatments that may be unavailable or may not be approved for use in Australia, or clinical trials that may not be operating locally. FoundationOne reports may contain information regarding treatments that may be unavailable or may not be approved for use in Australia, or clinical trials that may not be operating locally.

Roche Products Pty Limited ABN 70 000 132 865 | Roche Diagnostics Australia Pty Limited ABN 29 003 001 205 | Roche Diabetes Care Australia Pty Limited ABN 69 602 140 278. This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances. To report a suspected side effect or product complaint associated with the use of a Roche product, visitor contact Roche Patient Safety atRoche acknowledges the Traditional Owners of Country throughout Australia. We pay our respects to Elders past and present.